Compare LAB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | MRVI |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.4M | 449.6M |
| IPO Year | 2011 | 2020 |
| Metric | LAB | MRVI |
|---|---|---|
| Price | $1.55 | $3.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.35 | ★ $4.57 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $169,737,000.00 | ★ $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 79.77 | N/A |
| 52 Week Low | $0.92 | $1.67 |
| 52 Week High | $2.14 | $6.21 |
| Indicator | LAB | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 61.96 |
| Support Level | $1.24 | $3.19 |
| Resistance Level | $1.34 | $4.02 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 61.22 | 78.18 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.